Compare LBRDA & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDA | TECH |
|---|---|---|
| Founded | 2014 | 1976 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.6B |
| IPO Year | N/A | 1995 |
| Metric | LBRDA | TECH |
|---|---|---|
| Price | $36.24 | $48.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $71.82 |
| AVG Volume (30 Days) | 181.1K | ★ 2.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | N/A | ★ $1,219,635,000.00 |
| Revenue This Year | N/A | $2.49 |
| Revenue Next Year | $109.28 | $6.40 |
| P/E Ratio | ★ $8.39 | $62.06 |
| Revenue Growth | N/A | ★ 5.23 |
| 52 Week Low | $36.23 | $45.12 |
| 52 Week High | $100.85 | $72.16 |
| Indicator | LBRDA | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 28.93 | 39.29 |
| Support Level | N/A | N/A |
| Resistance Level | $48.97 | $60.88 |
| Average True Range (ATR) | 2.78 | 3.59 |
| MACD | -1.03 | -0.80 |
| Stochastic Oscillator | 0.26 | 18.47 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.